FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...

Certain cancers can now be frozen inside your body. Yes, you heard it right. In what could be a significant leap in minimally invasive oncology, Liverpool Hospi ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ — Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

Global Urology Imaging Systems Market OverviewThe global urology imaging systems market is expected to register steady growth ...

With cancer cases rising sharply across India, the search for more precise, less invasive and patient-friendly treatments has ...

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...

Vir Biotechnology, Inc. ( VIR) Q4 2025 Earnings Call February 23, 2026 5:30 PM EST ...

Tech tycoons, podcast bros and Hollywood stars are all piling money into full-body scans, which deploy AI in the hope of catching everything from high cholesterol to cancer. Is this the first step to ...

Paramagnetic rim lesions may help assess MS risk in people with radiologically isolated syndrome before symptoms appear.

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.